TABLE 1GENDER-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2023)
TABLE 2GENDER-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2024-2030)
TABLE 3AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2023)
TABLE 4AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2024-2030)
TABLE 5STAGE-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2023)
TABLE 6STAGE-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2024-2030)
TABLE 7EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2023)
TABLE 8EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2024-2030)
TABLE 9SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2023)
TABLE 10SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2024-2030)
TABLE 11GENDER-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2023)
TABLE 12GENDER-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2024-2030)
TABLE 13AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2023)
TABLE 14AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2024-2030)
TABLE 15STAGE-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2023)
TABLE 16STAGE-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2024-2030)
TABLE 17EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2023)
TABLE 18EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2024-2030)
TABLE 19SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2023)
TABLE 20SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2024-2030)
TABLE 21GENDER-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2023)
TABLE 22GENDER-SPECIFIC INCIDENCE OF STS IN THE ITALY (2024-2030)
TABLE 23AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2023)
TABLE 24AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE ITALY (2024-2030)
TABLE 25STAGE-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2023)
TABLE 26STAGE-SPECIFIC INCIDENCE OF STS IN THE ITALY (2024-2030)
TABLE 27EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2023)
TABLE 28EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE ITALY (2024-2030)
TABLE 29SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2023)
TABLE 30SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE ITALY (2024-2030)
TABLE 31GENDER-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2023)
TABLE 32GENDER-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2024-2030)
TABLE 33AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2023)
TABLE 34AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2024-2030)
TABLE 35STAGE-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2023)
TABLE 36STAGE-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2024-2030)
TABLE 37EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2023)
TABLE 38EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2024-2030)
TABLE 39SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2023)
TABLE 40SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2024-2030)
TABLE 41GENDER-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2023)
TABLE 42GENDER-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2024-2030)
TABLE 43AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2023)
TABLE 44AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2024-2030)
TABLE 45STAGE-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2023)
TABLE 46STAGE-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2024-2030)
TABLE 47EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2023)
TABLE 48EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2024-2030)
TABLE 49SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2023)
TABLE 50SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2024-2030)
TABLE 51GENDER-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2023)
TABLE 52GENDER-SPECIFIC INCIDENCE OF STS IN THE UK (2024-2030)
TABLE 53AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2023)
TABLE 54AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE UK (2024-2030)
TABLE 55STAGE-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2023)
TABLE 56STAGE-SPECIFIC INCIDENCE OF STS IN THE UK (2024-2030)
TABLE 57EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2023)
TABLE 58EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE UK (2024-2030)
TABLE 59SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2023)
TABLE 60SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE UK (2024-2030)
TABLE 61GENDER-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2023)
TABLE 62GENDER-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2024-2030)
TABLE 63AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2023)
TABLE 64AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2024-2030)
TABLE 65STAGE-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2023)
TABLE 66STAGE-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2024-2030)
TABLE 67EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2023)
TABLE 68EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2024-2030)
TABLE 69SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2023)
TABLE 70SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2024-2030)
TABLE 71MARKET SIZE OF METASTATIC SOFT TISSUE SARCOMA (STS) 2017-2023 IN THE 7MM (USD MILLION)
TABLE 72MARKET SIZE OF METASTATIC SOFT TISSUE SARCOMA (STS) 2024-2030 IN THE 7MM (USD MILLION)
TABLE 73MARKET SIZE OF METASTATIC SOFT TISSUE SARCOMA (STS) BY THERAPIES 2017-2023 IN THE 7MM (USD MILLION)
TABLE 74MARKET SIZE OF METASTATIC SOFT TISSUE SARCOMA (STS) BY THERAPIES 2024-2030 IN THE 7MM (USD MILLION)
TABLE 75US: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023, USD MILLION
TABLE 76US: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030, USD MILLION
TABLE 77US: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023, USD MILLION
TABLE 78US: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030, USD MILLION
TABLE 79GERMANY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023 (USD MILLION)
TABLE 80GERMANY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030 (USD MILLION)
TABLE 81GERMANY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023 (USD MILLION)
TABLE 82GERMANY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030 (USD MILLION)
TABLE 83UK: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023 (USD MILLION)
TABLE 84UK: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030 (USD MILLION)
TABLE 85UK: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023 (USD MILLION)
TABLE 86UK: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030 (USD MILLION)
TABLE 87FRANCE: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023 (USD MILLION)
TABLE 88FRANCE: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030 (USD MILLION)
TABLE 89FRANCE: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023 (USD MILLION)
TABLE 90FRANCE: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030 (USD MILLION)
TABLE 91ITALY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023 (USD MILLION)
TABLE 92ITALY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030 (USD MILLION)
TABLE 93ITALY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023 (USD MILLION)
TABLE 94ITALY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030 (USD MILLION)
TABLE 95SPAIN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023 (USD MILLION)
TABLE 96SPAIN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030 (USD MILLION)
TABLE 97SPAIN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023 (USD MILLION)
TABLE 98SPAIN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030 (USD MILLION)
TABLE 99JAPAN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2017-2023 (USD MILLION)
TABLE 100JAPAN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), 2024-2030 (USD MILLION)
TABLE 101JAPAN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2023 (USD MILLION)
TABLE 102JAPAN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2024-2030 (USD MILLION)

FIGURE 1TOTAL PREVALENT POPULATION OF STS BY 7MM (2017-2030)
FIGURE 27 MM STS MARKET SIZE, 2019 & 2030
FIGURE 37MM STS MARKET, BY INCIDENT PATIENT IN 2019 & 2030
FIGURE 4INCIDENCE OF STSS IN 7MM
FIGURE 5REGIONAL SNAPSHOT, SEGMENT SHARE (%), 2019
FIGURE 6TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE UNITED STATES (2017-2030)
FIGURE 7GENDER-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2030)
FIGURE 8AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2030)
FIGURE 9STAGE-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2030)
FIGURE 10EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2030)
FIGURE 11SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE UNITED STATES (2017-2030)
FIGURE 12REGIONAL SNAPSHOT, SEGMENT SHARE (%), 2019
FIGURE 13TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE GERMANY (2017-2030)
FIGURE 14GENDER-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2030)
FIGURE 15AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2030)
FIGURE 16STAGE-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2030)
FIGURE 17EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2030)
FIGURE 18SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE GERMANY (2017-2030)
FIGURE 19TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE ITALY (2017-2030)
FIGURE 20GENDER-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2030)
FIGURE 21AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2030)
FIGURE 22STAGE-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2030)
FIGURE 23EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2030)
FIGURE 24SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE ITALY (2017-2030)
FIGURE 25TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE FRANCE (2017-2030)
FIGURE 26GENDER-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2030)
FIGURE 27AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2030)
FIGURE 28STAGE-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2030)
FIGURE 29EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2030)
FIGURE 30SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE FRANCE (2017-2030)
FIGURE 31TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE SPAIN (2017-2030)
FIGURE 32GENDER-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2030)
FIGURE 33AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2030)
FIGURE 34STAGE-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2030)
FIGURE 35EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2030)
FIGURE 36SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE SPAIN (2017-2030)
FIGURE 37TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE UK (2017-2030)
FIGURE 38GENDER-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2030)
FIGURE 39AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2030)
FIGURE 40STAGE-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2030)
FIGURE 41EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2030)
FIGURE 42SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE UK (2017-2030)
FIGURE 43REGIONAL SNAPSHOT, SEGMENT SHARE (%), 2019
FIGURE 44TOTAL INCIDENT CASES OF SOFT TISSUE SARCOMA (STS) IN THE JAPAN (2017-2030)
FIGURE 45GENDER-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2030)
FIGURE 46AGE GROUP-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2030)
FIGURE 47STAGE-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2030)
FIGURE 48EXTREMITIES-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2030)
FIGURE 49SUB-GROUP-SPECIFIC INCIDENCE OF STS IN THE JAPAN (2017-2030)
FIGURE 50RECENTLY LAUNCHED THERAPIES
FIGURE 51MARKET SHARE SEGMENTATION OF 7MM COUNTRIES IN 2030
FIGURE 52US: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 53GERMANY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 54UK: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 55FRANCE: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 56ITALY: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 57SPAIN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 58JAPAN: MARKET SIZE OF SOFT TISSUE SARCOMA (STS), BY THERAPY, 2017-2030 (USD MILLION)
FIGURE 59DRIVERS & RESTRAIN
FIGURE 60DRIVERS IMPACT ANALYSIS
FIGURE 61RESTRAINTS IMPACT ANALYSIS